The US FDA has approved the Revvity Auto-Pure 2400 liquid handling platform with T-SPOT.TB test. Initially launched in 2024, this combination is designed to enable laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This marks an advancement in the fight against TB with a fast, high-throughput solution delivering accurate diagnostic results to support timely treatment and containment.